Published in Mol Ther on April 03, 2012
Bioreducible polycations in nucleic acid delivery: past, present, and future trends. Macromol Biosci (2014) 0.93
Bioreducible polymers for therapeutic gene delivery. J Control Release (2014) 0.87
Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats. J Control Release (2013) 0.82
Functional polymers of gene delivery for treatment of myocardial infarct. J Control Release (2014) 0.80
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Drug delivery systems: entering the mainstream. Science (2004) 9.27
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 5.57
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis (2006) 5.28
Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol (2008) 4.42
Erythropoietin. Blood (1991) 4.37
Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (2001) 4.35
Role of the kidney in erythropoiesis. Nature (1957) 3.75
Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 3.37
Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 3.04
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99
Biopharmaceutical benchmarks 2010. Nat Biotechnol (2010) 2.80
Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev (2005) 2.70
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 2.55
Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood (1991) 2.52
Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood (1991) 2.41
Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther (1999) 2.17
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol (2010) 2.16
Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood (1988) 2.13
Erythropoietins: a common mechanism of action. Exp Hematol (2008) 1.89
Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev (2007) 1.73
Anemia of end-stage renal disease (ESRD). Kidney Int (1985) 1.63
Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm (2010) 1.60
Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials (2008) 1.55
Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov (2006) 1.52
Gene therapeutics. Nature (1991) 1.39
Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med (1977) 1.32
Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev (2003) 1.25
Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood (1998) 1.21
Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol (2006) 1.21
Nonrenal regulation of EPO synthesis. Kidney Int (2009) 1.20
Intracellular cargo delivery using tat peptide and derivatives. Med Res Rev (2004) 1.09
Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab (2000) 1.09
Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood (1988) 1.09
Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Kidney Int (1991) 1.07
Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Ther (2005) 1.07
Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther (2007) 1.04
Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophys J (2008) 0.97
Non-viral gene delivery carrier and its three-dimensional transfection system. Int J Pharm (2009) 0.95
The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif (2010) 0.93
Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther (2007) 0.88
Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. J Control Release (2011) 0.83
Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment. Exp Hematol (1993) 0.81
Gene therapy on trial. Science (2000) 0.79
Emerging technologies in the delivery of erythropoietin for therapeutics. Med Res Rev (2011) 0.79
NIH under fire over gene-therapy trials... Nature (2000) 0.76
Human gene therapy. First experiment approved. Nature (1990) 0.76
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 3.04
Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int (2005) 3.03
Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev (2002) 2.54
Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release (2008) 2.15
Immediate initiation of CAPD following percutaneous catheter placement without break-in procedure. Perit Dial Int (2007) 1.95
Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res (2005) 1.91
Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther (2006) 1.79
Reducible poly(amido ethylenimine)s designed for triggered intracellular gene delivery. Bioconjug Chem (2006) 1.77
In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release (2008) 1.67
Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant (2006) 1.63
Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int (2004) 1.56
Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials (2008) 1.55
Validation of a multi-frequency electrical impedance tomography (mfEIT) system KHU Mark1: impedance spectroscopy and time-difference imaging. Physiol Meas (2008) 1.50
Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res (2008) 1.46
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release (2006) 1.44
Multilevel surgery in patients with rapid eye movement-related obstructive sleep apnea. Otolaryngol Head Neck Surg (2009) 1.43
Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem (2008) 1.43
Magnetic resonance imaging (MRI) assessment of ventricular remodeling after myocardial infarction in rabbits. Comp Med (2012) 1.42
Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction. J Control Release (2012) 1.41
Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials (2007) 1.35
Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release (2004) 1.34
Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials (2011) 1.22
VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm (2009) 1.21
Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res (2005) 1.20
Biodegradable poly(ethylenimine) for plasmid DNA delivery. J Control Release (2002) 1.19
Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev (2002) 1.18
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther (2009) 1.11
An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther (2002) 1.11
Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res (2010) 1.10
A family of bioreducible poly(disulfide amine)s for gene delivery. Biomaterials (2009) 1.10
Novel pH sensitive block copolymer micelles for solvent free drug loading. Macromol Biosci (2006) 1.08
Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery. J Control Release (2006) 1.06
Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther (2011) 1.05
Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev (2011) 1.04
The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials (2009) 1.04
Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther (2005) 1.02
Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release (2007) 1.02
Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release (2005) 1.01
Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm Res (2004) 1.01
A guanidinylated bioreducible polymer with high nuclear localization ability for gene delivery systems. Biomaterials (2009) 1.00
Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther (2005) 0.99
Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release (2009) 0.99
Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J Control Release (2003) 0.98
Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol (2004) 0.98
Ligation of the left circumflex coronary artery with subsequent MRI and histopathology in rabbits. J Am Assoc Lab Anim Sci (2010) 0.98
Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin. Biomaterials (2004) 0.97
Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem (2006) 0.97
Synthesis of biodegradable multi-block copolymers of poly(L-lysine) and poly(ethylene glycol) as a non-viral gene carrier. J Control Release (2004) 0.97
Mixtures of poly(triethylenetetramine/cystamine bisacrylamide) and poly(triethylenetetramine/cystamine bisacrylamide)-g-poly(ethylene glycol) for improved gene delivery. Bioconjug Chem (2010) 0.97
A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J Control Release (2003) 0.96
Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. J Control Release (2008) 0.96
Polymeric gene carriers. Crit Rev Eukaryot Gene Expr (2005) 0.96
Bioreducible polymer-transfected skeletal myoblasts for VEGF delivery to acutely ischemic myocardium. Biomaterials (2010) 0.96
Caprolactonic poloxamer analog: PEG-PCL-PEG. Biomacromolecules (2005) 0.96
Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials (2011) 0.96
Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials (2011) 0.95
GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther (2003) 0.95
Feasibility of breast cancer lesion detection using a multi-frequency trans-admittance scanner (TAS) with 10 Hz to 500 kHz bandwidth. Physiol Meas (2007) 0.95
Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrology (Carlton) (2009) 0.95
Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release (2002) 0.94
Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem (2003) 0.94
Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med (2003) 0.94
Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine (Phila Pa 1976) (2005) 0.94
Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci Lett (2010) 0.93
LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem (2008) 0.93
Polymeric gene carrier for insulin secreting cells: poly(L-lysine)-g-sulfonylurea for receptor mediated transfection. J Control Release (2005) 0.93
Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis. Biomaterials (2008) 0.92
Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther (2004) 0.92
Dendrimer type bio-reducible polymer for efficient gene delivery. J Control Release (2012) 0.92
Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release (2006) 0.92
Apatite-coated collagen scaffold for bone morphogenetic protein-2 delivery. Tissue Eng Part A (2011) 0.92
Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials (2011) 0.91
Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. J Sex Med (2008) 0.91
Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Deliv Rev (2009) 0.91
Poly(L-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA. J Drug Target (2007) 0.90
Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials (2011) 0.90